To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study
Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine, Solna, Sweden; Department of Clinical Science and Education, Södersjukhuse, Stockholm, Sweden.; Sachs’ Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden..
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Surgery, Randers Regional Hospital, Randers, Denmark.
Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine, Stockholm, Sweden.
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Surgery, Randers Regional Hospital, Randers, Denmark.
Show others and affiliations
2020 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 395, no 10218, p. 123-131Article in journal (Refereed) Published
Abstract [en]

Background: Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance paradigms, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account, such as by assessing CRC incidence by tumour stage, or stage-adjusted mortality from CRC. We aimed to compare both overall and country-specific risks of CRC mortality and incident CRC among patients with UC.

Methods: In this population-based cohort study of 96 447 patients with UC in Denmark (n=32 919) and Sweden (n=63 528), patients were followed up for CRC incidence and CRC mortality between Jan 1, 1969, and Dec 31, 2017, and compared with matched reference individuals from the general population (n=949 207). Patients with UC were selected from national registers and included in the analysis if they had two or more records with a relevant International Classification of Disease in the patient register (in the country in question) or one such record plus a colorectal biopsy report with a morphology code suggestive of inflammatory bowel disease. For every patient with UC, we selected matched reference individuals from the total population registers of Denmark and Sweden, who were matched for sex, age, birth year, and place of residence. We used Cox regression to compute hazard ratios (HRs) for incident CRC, and for CRC mortality, taking tumour stage into account.

Findings: During follow-up, we observed 1336 incident CRCs in the UC cohort (1.29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0.82 per 1000 person-years; HR 1.66, 95% CI 1.57-1.76). In the UC cohort, 639 patients died from CRC (0.55 per 1000 person-years), compared with 4451 reference individuals (0.38 per 1000 person-years; HR 1.59, 95% CI 1.46-1.72) during the same time period. The CRC stage distribution in people with UC was less advanced (p<0.0001) than in matched reference individuals, but taking tumour stage into account, patients with UC and CRC remained at increased risk of CRC death (HR 1.54, 95% CI 1.33-1.78). The excess risks declined over calendar periods: during the last 5 years of follow-up (2013-17, Sweden only), the HR for incident CRC in people with UC was 1.38 (95% CI 1.20-1.60, or one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1.25 (95% CI 1.03-1.51, or one additional case per 3041 patients with UC per 5 years).

Interpretation: Compared with those without UC, individuals with UC are at increased risk of developing CRC, are diagnosed with less advanced CRC, and are at increased risk of dying from CRC, although these excess risks have declined substantially over time. There still seems to be room for improvement in international surveillance guidelines.

Place, publisher, year, edition, pages
Elsevier, 2020. Vol. 395, no 10218, p. 123-131
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-79372DOI: 10.1016/s0140-6736(19)32545-0ISI: 000506652400029PubMedID: 31929014OAI: oai:DiVA.org:oru-79372DiVA, id: diva2:1388666
Funder
Stockholm County CouncilSwedish Cancer SocietySwedish Research CouncilForte, Swedish Research Council for Health, Working Life and WelfareThe Karolinska Institutet's Research FoundationSwedish Foundation for Strategic Research
Note

Funding Agencies:

Swedish Medical Society (Fund for Research in Gastroenterology)  

Swedish Medical Society (Ihre Foundation)  

Mag-tarmfonden  

Young Scholar Award from the Strategic Research Area Epidemiology programme at Karolinska Institutet 

Independent Research Fund Denmark

Available from: 2020-01-27 Created: 2020-01-27 Last updated: 2022-03-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Halfvarson, JonasLudvigsson, Jonas F.

Search in DiVA

By author/editor
Halfvarson, JonasLudvigsson, Jonas F.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
The Lancet
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 342 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf